B1962
As of the edition of 20 October 2026, B1962 is a drug known only by a code name: in active development; acts on CD274 and VEGFA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 2 | 0 | 2 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tasly Pharmaceutical | Lead sponsor of trials | 2022 to now |